Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

▤ Summary

Vera Therapeutics refinanced its existing Oxford Finance debt facility with a new credit agreement that can provide up to $500 million in term loans. The company increased its initial borrowing to $75 million and expanded discretionary future borrowing capacity, while also lowering its borrowing cost and extending maturity. Management said the new structure improves financial flexibility and supports the planned BLA submission for atacicept in IgA nephropathy. Vera also said the stronger capital position will help prepare for a potential commercial launch in 2026 and support broader strategic initiatives.

▦ Linked Companies